Norepinephrine: the next therapeutics frontier for Parkinson's disease.

Transl Neurodegener · 2012 · PMC3506997 · PMID 23211006

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The NE re-uptake inhibitor atomoxetine showed a trend for improving several frontal lobe measures of cognitive performance in a small open-label study of non-demented PD patients [ 24 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.